<DOC>
	<DOCNO>NCT02269644</DOCNO>
	<brief_summary>This study double-blind , randomize , multicenter trial ass safety efficacy single 1500 mg IV dose dalbavancin plus single 500 mg IV dose azithromycin comparison approve antibiotic regimen linezolid 600 mg every 12 hour 10-14 day plus single 500 mg IV dose azithromycin treatment Community Acquired Bacterial Pneumonia .</brief_summary>
	<brief_title>A P3 Comparator Trial Community Acquired Bacterial Pneumonia</brief_title>
	<detailed_description>This study double-blind , randomize , multicenter trial ass safety efficacy single 1500 mg IV dose dalbavancin plus single 500 mg IV dose azithromycin comparison approve antibiotic regimen linezolid 600 mg every 12 hour 10-14 day plus single 500 mg IV dose azithromycin treatment CABP . Adult patient meet inclusion none exclusion criterion randomize one two treatment arm . Dosing commence Day 1 , patient receive minimum 10 day therapy . Patients assess Day 1 , Day 4-5 , Day 7 , Day 14 ( End Therapy , EOT ) , Day 28 ( Follow ) .</detailed_description>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Bacterial</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>1 . Adults age 18 85 , inclusive 2 . Has give write , inform consent 3 . Has acute illness onset within previous 7 day 4 . Has least 2 follow symptom : Difficulty breathe shortness breath Cough Production purulent sputum Pleuritic chest pain 5 . Has least 2 vital sign abnormality : Fever ( &gt; 38°C &lt; 35°C ) Hypotension ( systolic BP &lt; 90 mm Hg ) Tachycardia ( &gt; 100 beat /min ) Tachypnea ( &gt; 24 breath /min ) 6 . Has least one clinical laboratory abnormality : Hypoxemia ( room air SaO2 &lt; 90 % ) Clinical evidence pulmonary consolidation Elevated WBC count neutropenia ( &gt; 12,000/mm3 &lt; 4,000/mm3 ) 7 . Has new lobar multilobar infiltrate chest radiograph 8 . Has CURB65 risk category 1 4 . Patients CURB65 risk category 1 limit 20 % total patient population 1 . Contraindication administration study treatment , hypersensitivity glycopeptide agent , betalactam agent , linezolid macrolide antibiotic , current recent ( within 2 week ) use MAO inhibitor serotonergic antidepressant ( within 5 week fluoxetine ) ( see Section 5.5.1 ) 2 . Has receive antibiotic therapy 4 day prior screen , follow exception : 25 % patient may receive single dose short acting ( half life &lt; 8 hour ) antibiotic 3 . Has aspiration pneumonia 4 . Has hospital acquire ventilator associate pneumonia , healthcare associate pneumonia , 2 day hospital previous 90 day 5 . Has cystic fibrosis know suspected Pneumocystis pneumonia know suspect active tuberculosis 6 . Females childbearing potential unable take adequate contraceptive precaution , positive pregnancy result within 24 hour prior study entry , know pregnant , currently breastfeed infant 7 . Has primary metastatic lung cancer 8 . Has know bronchial obstruction history postobstructive pneumonia 9 . Requires admission ICU baseline 10 . Has empyema require drainage 11 . Infection due organism know prior study entry resistant either treatment regimen 12 . Has know suspect infection due solely atypical pathogen Mycoplasma sp. , Chlamydia sp . Legionella sp . positive Legionella urinary antigen baseline 13 . Absolute neutrophil count &lt; 500 cells/mm3 14 . Known suspected human immunodeficiency virus ( HIV ) infect patient CD4 cell count &lt; 200 cells/mm3 past current acquire immunodeficiency syndrome ( AIDS ) define condition unknown CD4 count 15 . Patients recent bone marrow transplant ( posttransplant hospital stay ) 16 . Patients receive oral steroid &gt; 40 mg prednisolone per day ( equivalent ) receive immunosuppressant drug organ transplantation 17 . Patients rapidly fatal illness , expect survive 3 month 18 . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make patient inappropriate entry study 19 . Has participate another trial investigational pharmaceutical product 30 day prior enrollment 20 . Prior participation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>